• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

延长潜伏期可改善对分枝杆菌属 Xenopi 感染的临床诊断,并允许对分枝杆菌菌株进行多种抗生素的药敏试验。

Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics.

机构信息

Residency in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy.

Chemical-clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

出版信息

J Glob Antimicrob Resist. 2020 Sep;22:533-537. doi: 10.1016/j.jgar.2020.04.028. Epub 2020 May 5.

DOI:10.1016/j.jgar.2020.04.028
PMID:32387259
Abstract

OBJECTIVES

Mycobacterium xenopi is a nontuberculous mycobacterium (NTM) whose clinical diagnosis and drug susceptibility studies are frequently hampered by poor in vitro growth. Extending the culture incubation time from 42 days (common-standard) to 56 days could improve the likelihood of diagnosis and provide strains for phenotypic drug susceptibility profiling of this poorly studied but clinically relevant mycobacterium.

METHODS

Time-to-positivity of mycobacterial cultures incubated for 56 days were analysed and compared. Clinical mycobacteriosis was defined by ATS/IDSA criteria. In vitro susceptibility of M. xenopi isolates was tested by broth microdilution.

RESULTS

Of 3852 mycobacteria-positive cultures (26 different mycobacterial species),M. xenopi required by far the longest growth time in culture, exceeding the 42 days commonly used in routine diagnostics in 41.2% of cases versus 4.7% for other NTM and 2.0% for Mycobacterium tuberculosis complex (P<0.001). Prolonging the incubation time to 56 days had a great impact on M. xenopi diagnosis, as 56.3% (27/48) of patients would have not fulfilled the ATS/IDSA criteria at an incubation limited to 42 days. All 40 M. xenopi isolates from patients with clinical mycobacteriosis were fully susceptibility to macrolides and rifamycins in vitro and to moxifloxacin, amikacin and linezolid.

CONCLUSION

These results indicate that a significant percentage (56.3%) of positive culture forM. xenopi would have incorrectly been reported as negative to clinicians without prolonging the incubation time to 56 days. Moreover, 56.3% of patients with M. xenopi disease would have missed the diagnosis along with an appropriate germ-based antimycobacterial treatment, otherwise fully effective.

摘要

目的

耻垢分枝杆菌是一种非结核分枝杆菌(NTM),其临床诊断和药敏研究经常因体外生长不良而受到阻碍。将培养孵育时间从 42 天(标准时间)延长至 56 天,可以提高诊断的可能性,并为这种研究较少但具有临床相关性的分枝杆菌提供用于表型药敏分析的菌株。

方法

分析并比较了培养 56 天的分枝杆菌阳性培养物的阳性时间。根据 ATS/IDSA 标准定义临床分枝杆菌病。通过肉汤微量稀释法测试耻垢分枝杆菌分离株的体外药敏性。

结果

在 3852 株分枝杆菌阳性培养物(26 种不同的分枝杆菌种)中,耻垢分枝杆菌在培养中所需的生长时间最长,在 41.2%的情况下超过了常规诊断中常用的 42 天,而其他 NTM 为 4.7%,结核分枝杆菌复合群为 2.0%(P<0.001)。将孵育时间延长至 56 天对耻垢分枝杆菌的诊断有很大的影响,因为在孵育时间限制为 42 天时,56.3%(27/48)的患者不符合 ATS/IDSA 标准。40 株来自有临床分枝杆菌病患者的耻垢分枝杆菌分离株在体外对大环内酯类和利福平类药物以及莫西沙星、阿米卡星和利奈唑胺完全敏感。

结论

这些结果表明,如果不将孵育时间延长至 56 天,临床医生会错误地报告耻垢分枝杆菌的阳性培养物中有很大比例(56.3%)为阴性。此外,56.3%的耻垢分枝杆菌病患者会错过诊断,从而无法接受适当的基于细菌的抗分枝杆菌治疗,而这些治疗原本是完全有效的。

相似文献

1
Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics.延长潜伏期可改善对分枝杆菌属 Xenopi 感染的临床诊断,并允许对分枝杆菌菌株进行多种抗生素的药敏试验。
J Glob Antimicrob Resist. 2020 Sep;22:533-537. doi: 10.1016/j.jgar.2020.04.028. Epub 2020 May 5.
2
Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.采用 slomyco 测试系统对缓慢生长非结核分枝杆菌进行药物敏感性测试。
PLoS One. 2018 Sep 17;13(9):e0203108. doi: 10.1371/journal.pone.0203108. eCollection 2018.
3
Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015-2020).日内瓦地区受关注的非结核分枝杆菌(2015-2020 年)。
Respiration. 2022;101(4):367-375. doi: 10.1159/000520033. Epub 2021 Dec 7.
4
[Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].[非结核分枝杆菌肺病——美国胸科学会/欧洲呼吸学会/欧洲临床微生物与感染病学会/美国感染病学会新指南]
Dtsch Med Wochenschr. 2020 Aug;145(16):1145-1151. doi: 10.1055/s-0043-124159. Epub 2020 Aug 13.
5
Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study.分枝杆菌感染与分枝杆菌复合群肺病的临床结局比较:一项回顾性匹配队列研究。
Respir Med. 2020 Jun;167:105967. doi: 10.1016/j.rmed.2020.105967. Epub 2020 Apr 15.
6
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection.意大利北部一家参考教学医院对偶发分枝杆菌病及抗菌药物敏感性水平的十年监测研究:HIV相关感染与非HIV相关感染
HIV Clin Trials. 2004 Jul-Aug;5(4):206-15. doi: 10.1310/H6H7-24BF-2MYB-LTLM.
7
Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria.中国临床分离株和非结核分枝杆菌参考株对 41 种药物的药敏性和 MIC 分布。
Int J Antimicrob Agents. 2017 Mar;49(3):364-374. doi: 10.1016/j.ijantimicag.2016.10.024. Epub 2016 Dec 21.
8
In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria.利奈唑胺对缓慢生长非结核分枝杆菌的体外活性
Antimicrob Agents Chemother. 2003 May;47(5):1736-8. doi: 10.1128/AAC.47.5.1736-1738.2003.
9
[Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey].[土耳其一家转诊医院肺部样本中常见的生长缓慢的非结核分枝杆菌及其药敏试验结果评估]
Mikrobiyol Bul. 2019 Jul;53(3):330-335. doi: 10.5578/mb.68091.
10
Species-Specific Risk Factors, Treatment Decisions, and Clinical Outcomes for Laboratory Isolates of Less Common Nontuberculous Mycobacteria in Washington State.华盛顿州少见非结核分枝杆菌实验室分离株的物种特异性风险因素、治疗决策及临床结果
Ann Am Thorac Soc. 2017 Jul;14(7):1129-1138. doi: 10.1513/AnnalsATS.201609-731OC.

引用本文的文献

1
GenoType CM Direct and VisionArray Myco for the Rapid Identification of Mycobacteria from Clinical Specimens.用于从临床标本中快速鉴定分枝杆菌的GenoType CM Direct和VisionArray Myco检测系统
J Clin Med. 2022 Apr 25;11(9):2404. doi: 10.3390/jcm11092404.